Harrison.ai has petitioned the FDA to exempt some radiology AI devices from premarket review, prompting mixed feedback from industry stakeholders.
Key Details
- 1Harrison.ai seeks FDA exemption for certain computer-aided detection (CAD) AI devices from premarket review.
- 2The company argues current US regulatory pathways are too burdensome for rapidly evolving AI.
- 3Stakeholder comments included feedback from RSNA, ACR, and Patient Alliance for Safe Imaging.
- 4ACR emphasized the need to prioritize patient safety and warned against unintended safety risks.
- 5Harrison.ai has 8 FDA clearances covering 12 indications and its products serve over 1,000 facilities in 40 countries.
- 6Consulting firm Rubrum Advising submitted the petition in October 2023.
Why It Matters
If granted, this exemption could significantly alter the regulatory landscape for radiology AI software, balancing innovation access against patient safety concerns. The decision will set a precedent for future AI device oversight in imaging.
Source
Radiology Business
Related News
•Radiology Business
CARPL.ai Raises $10M to Expand Radiology AI Marketplace
CARPL.ai secured $10M in Series A funding to expand its global radiology AI marketplace.
•HealthExec
AI Reimbursement, Biomedical Research, and Exec Survey Highlight Healthcare Trends
Healthcare AI adoption is rising, but ROI measurement and clinical impact remain key challenges.
•HealthExec
Senate Vote Fails to Block AI Medicare Prior Authorization Pilot
A Senate vote failed to halt the WISeR AI-based prior authorization pilot for traditional Medicare claims.